X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON LTD ALKEM LABORATORIES/
BIOCON LTD
 
P/E (TTM) x - 94.5 - View Chart
P/BV x 6.7 7.7 86.5% View Chart
Dividend Yield % 0.6 0.2 404.2%  

Financials

 ALKEM LABORATORIES   BIOCON LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
BIOCON LTD
Mar-17
ALKEM LABORATORIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,162 136.8%   
Low Rs1,232483 255.3%   
Sales per share (Unadj.) Rs417.5194.6 214.6%  
Earnings per share (Unadj.) Rs56.334.4 163.6%  
Cash flow per share (Unadj.) Rs64.748.3 134.1%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.1 740.3%  
Book value per share (Unadj.) Rs292.9241.9 121.1%  
Shares outstanding (eoy) m119.57200.00 59.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.2 80.0%   
Avg P/E ratio x25.123.9 104.8%  
P/CF ratio (eoy) x21.817.0 128.0%  
Price / Book Value ratio x4.83.4 141.7%  
Dividend payout %22.62.9 776.2%   
Avg Mkt Cap Rs m168,653164,440 102.6%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m9,1717,470 122.8%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m49,91538,911 128.3%  
Other income Rs m1,6451,571 104.7%   
Total revenues Rs m51,56140,482 127.4%   
Gross profit Rs m8,4829,795 86.6%  
Depreciation Rs m1,0062,772 36.3%   
Interest Rs m671260 257.9%   
Profit before tax Rs m8,4518,334 101.4%   
Minority Interest Rs m-114163 -69.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,616 99.4%   
Profit after tax Rs m6,7316,881 97.8%  
Gross profit margin %17.025.2 67.5%  
Effective tax rate %19.019.4 98.0%   
Net profit margin %13.517.7 76.3%  
BALANCE SHEET DATA
Current assets Rs m27,06240,477 66.9%   
Current liabilities Rs m15,32416,783 91.3%   
Net working cap to sales %23.560.9 38.6%  
Current ratio x1.82.4 73.2%  
Inventory Days Days6760 111.6%  
Debtors Days Days4183 49.8%  
Net fixed assets Rs m12,61045,073 28.0%   
Share capital Rs m2391,000 23.9%   
"Free" reserves Rs m34,49047,377 72.8%   
Net worth Rs m35,02748,377 72.4%   
Long term debt Rs m1,21221,082 5.7%   
Total assets Rs m54,38793,942 57.9%  
Interest coverage x13.633.1 41.2%   
Debt to equity ratio x00.4 7.9%  
Sales to assets ratio x0.90.4 221.6%   
Return on assets %13.67.6 179.0%  
Return on equity %19.214.2 135.1%  
Return on capital %24.912.6 197.2%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56312,988 50.5%   
Fx outflow Rs m3,0127,899 38.1%   
Net fx Rs m3,5525,089 69.8%   
CASH FLOW
From Operations Rs m7,2596,400 113.4%  
From Investments Rs m1,864-4,985 -37.4%  
From Financial Activity Rs m-9,273-1,775 522.4%  
Net Cashflow Rs m-150-473 31.7%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ASTRAZENECA PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jun 18, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS